McMillan E M, Wasik R, Peters S, Jackson I, Stoneking L, Everett M A
Cancer. 1983 Apr 15;51(8):1403-7. doi: 10.1002/1097-0142(19830415)51:8<1403::aid-cncr2820510813>3.0.co;2-p.
A monoclonal antibody OKT 9 which detects a determinant expressed by a variety of proliferating cell types has been recently developed. This antibody was used in conjunction with the immunoperoxidase technique to study the cutaneous lymphoid infiltrates of nine patients with mycosis fungoides, one patient with lymphomatoid papulosis, two patients with Sézary syndrome, and ten patients with large plaque atrophic parapsoriasis (a condition which may terminate in overt mycosis fungoides.) OKT 9 reactive cells were identified in all cases of mycosis fungoides examined, in one case of lymphomatoid papulosis, one of two cases of Sézary syndrome, and one of ten cases of large plaque atrophic parapsoriasis. These results suggest that further studies using OKT 9 should be performed to assess whether OKT 9 reactivity may be used as a prognostic marker in cutaneous lymphomas and prelymphomas.
一种能检测多种增殖细胞类型所表达决定簇的单克隆抗体OKT 9最近已研制出来。该抗体与免疫过氧化物酶技术联合使用,对9例蕈样肉芽肿患者、1例淋巴瘤样丘疹病患者、2例Sezary综合征患者以及10例大斑块萎缩性副银屑病患者(一种可能发展为明显蕈样肉芽肿的疾病)的皮肤淋巴浸润进行了研究。在所检查的所有蕈样肉芽肿病例、1例淋巴瘤样丘疹病、2例Sezary综合征中的1例以及10例大斑块萎缩性副银屑病中的1例中均发现了OKT 9反应性细胞。这些结果表明,应使用OKT 9进行进一步研究,以评估OKT 9反应性是否可作为皮肤淋巴瘤和淋巴瘤前期的预后标志物。